Anticancer Drugs

The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myel...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2019
Language:English
Physical Description:1 electronic resource (214 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03879nam-a2200925z--4500
001 993548401904498
005 20231214133528.0
006 m o d
007 cr|mn|---annan
008 202102s2019 xx |||||o ||| 0|eng d
020 |a 3-03921-587-6 
035 |a (CKB)4100000010106178 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/40955 
035 |a (EXLCZ)994100000010106178 
041 0 |a eng 
100 1 |a O’Boyle, Niamh M  |4 auth 
245 1 0 |a Anticancer Drugs 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2019 
300 |a 1 electronic resource (214 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients. 
546 |a English 
653 |a graphene oxide 
653 |a indole 
653 |a androgens 
653 |a cyclooxygenase-2 
653 |a cyclooxygenase-1 
653 |a heteropolysaccharide 
653 |a drug conjugation 
653 |a drug delivery 
653 |a ellipticine 
653 |a chemical linker 
653 |a oesophageal cancer 
653 |a antiproliferative activity 
653 |a topoisomerase II 
653 |a ?-lactam 
653 |a DSD 
653 |a antibody 
653 |a topoisomerase inhibitors 
653 |a magnetic targeting 
653 |a cisplatin resistance 
653 |a steroidogenesis 
653 |a [18F]FDG PET/CT 
653 |a heterocyclic chemistry 
653 |a dehydroepiandrosterone 
653 |a antimitotic 
653 |a 3-vinylazetidin-2-ones 
653 |a glioblastoma 
653 |a and cancer therapy 
653 |a intestinal mucositis 
653 |a Combretastatin A-4 
653 |a metabolism 
653 |a anti-cancer drugs 
653 |a maghemite 
653 |a COX-1 inhibitor 
653 |a anticancer 
653 |a CYP17A1 
653 |a conjugate and hybrid drugs 
653 |a inflammation 
653 |a snticancer drugs 
653 |a P450c17 
653 |a tumorigenesis 
653 |a cisplatin 
653 |a biomarker profiling 
653 |a cancer drug design 
653 |a tubulin 
653 |a cytochrome P450 
653 |a 5-fluorouracil 
653 |a prostate cancer 
653 |a abiraterone 
653 |a NCI screen 
653 |a radiation 
653 |a cancer immunotherapy 
653 |a microtubule targeted drugs 
653 |a cancer 
653 |a treatment resistance 
776 |z 3-03921-586-8 
700 1 |a Meegan, Mary J  |4 auth 
906 |a BOOK 
ADM |b 2023-12-15 05:56:46 Europe/Vienna  |f system  |c marc21  |a 2020-02-01 22:26:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338783130004498&Force_direct=true  |Z 5338783130004498  |b Available  |8 5338783130004498